Success Story: A Biostatistician Earns NIW Approval without an RFE Thanks to Our Expert Assistance
Client’s Testimonial:
"Thank you for your confirmation. I am glad to know my I-140 form has finally been approved!”
On March 20th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Biostatistician in the Field of Biostatistics (Approval Notice).
General Field: Biostatistics
Position at the Time of Case Filing: Biostatistician
Country of Origin: Taiwan
State of Residence at the Time of Filing: Texas
Approval Notice Date: March 20th, 2026
Processing Time: 17 months, 17 days (20 Days After Premium Processing Upgrade Was Requested)
Case Summary:
This approval marks another successful NIW case for a Taiwanese biostatistician whose work sits at the intersection of clinical research and quantitative methodology. The proposed endeavor is to continue developing and applying more effective approaches to clinical trial design and longitudinal analysis, to strengthen how medical studies are conducted and interpreted, ultimately improving the quality of evidence that informs treatment decisions and patient care.
At the time of filing, the petitioner was already advancing this work through an active research position in the United States. In just 20 days after upgrading to premium processing, the petition was approved without an RFE, an outcome that reflects both the strength of the petitioner's record and the thoroughness of the petition our team prepared on their behalf.
Research with National Importance
In the petition, we demonstrated substantial merit and national importance by linking the proposed endeavor to critical U.S. priorities in pharmaceutical R&D and public health. The United States leads the world in pharmaceutical development, yet the current drug development process remains costly and time-consuming. Improving clinical trial designs directly addresses this challenge and holds meaningful potential to reduce development costs and accelerate the delivery of new treatments to patients.
Academic Contributions and Recognition
The petition documented an established record of scholarly output and peer recognition. The published work includes 4 peer-reviewed journal articles (2 of them first-authored) and 1 conference abstract. These publications have received 21 citations from researchers around the world, reflecting meaningful reliance by the broader academic community.
We further highlighted that the research has been supported by funding from the National Institute of Allergy and Infectious Diseases (NIAID) and the Bill & Melinda Gates Foundation, two of the most selective and prestigious funders in global health and infectious disease research, as additional evidence of the recognized importance of this work.
Expert Endorsements
The filing included four expert recommendation letters from leading academics and practitioners. Together, these letters served to corroborate the petition's central arguments: that the proposed endeavor carries genuine national importance, that the petitioner has the expertise and track record to advance it, and that granting the waiver would directly benefit the United States. As one expert stated:
"It is imperative that he be allowed to carry out his research uninterrupted so that the United States can continue to benefit fully from its value."
NIW Approval and Outlook
In the filing, we showed that the endeavor has substantial merit and national importance, and that the petitioner is well-positioned to advance it through a strong publication, citation, and peer-recognition record backed by major research funding. We are proud to have supported this petitioner through the process and look forward to seeing the continued contributions this work will bring to medical research and public health in the United States.